메뉴 건너뛰기




Volumn 17, Issue 5, 2009, Pages 375-382

Implementation of a Canadian external quality assurance program for breast cancer biomarkers: An initiative of Canadian Quality Control in Immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) national standards committee/immunohistochemistry

(25)  Terry, Jefferson a   Torlakovic, Emina Emilia e,f   Garratt, John a   Miller, Denise e,f   Köbel, Martin a   Cooper, Jesse a   Bahzad, Shakir e   Pilavdzic, Dragana h   O'Malley, Frances k   O'Brien, Anne E m   SenGupta, Sandip l   Alport, Edward g   Têtu, Bernard j   Knight, Bryan b   Pettigrew, Norman M n   Berendt, Richard o   Wolber, Robert d   Trotter, Martin J p   Riddell, Robert H k   Gaboury, Louis i   more..


Author keywords

cIQc; ER; External quality assurance; HER2; Immunohistochemistry; PR

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

EID: 70349755835     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31819adacf     Document Type: Article
Times cited : (32)

References (21)
  • 1
    • 36849069347 scopus 로고    scopus 로고
    • American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    • Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312.
    • (2007) J Clin Oncol , vol.25 , pp. 5287-5312
    • Harris, L.1    Fritsche, H.2    Mennel, R.3
  • 3
    • 0034070040 scopus 로고    scopus 로고
    • Immunohistochemical demonstration of oestrogen and progesterone receptors: Correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries
    • DOI 10.1136/jcp.53.4.292
    • Rhodes A, Jasani B, Balaton AJ, et al. Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries. J Clin Pathol. 2000;53:292-301. (Pubitemid 30180402)
    • (2000) Journal of Clinical Pathology , vol.53 , Issue.4 , pp. 292-301
    • Rhodes, A.1    Jasani, B.2    Balaton, A.J.3    Miller, K.D.4
  • 4
    • 36049042990 scopus 로고    scopus 로고
    • Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: Results of the RCPA Quality Assurance Program
    • DOI 10.1136/jcp.2006.044701
    • Francis GD, Dimech M, Giles L, et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60:1277-1283. (Pubitemid 350084552)
    • (2007) Journal of Clinical Pathology , vol.60 , Issue.11 , pp. 1277-1283
    • Francis, G.D.1    Dimech, M.2    Giles, L.3    Hopkins, A.4
  • 5
    • 0035228849 scopus 로고    scopus 로고
    • Study of Interlaboratory Reliability and Reproducibility of Estrogen and Progesterone Receptor Assays in Europe: Documentation of Poor Reliability and Identification of Insufficient Microwave Antigen Retrieval Time as a Major Contributory Element of Unreliable Assays
    • DOI 10.1309/H905-HYC1-6UQQ-981P
    • Rhodes A, Jasani B, Balaton AJ, et al. Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol. 2001; 115:44-58. (Pubitemid 33695090)
    • (2001) American Journal of Clinical Pathology , vol.115 , Issue.1 , pp. 44-58
    • Rhodes, A.1    Jasani, B.2    Balaton, A.J.3    Barnes, D.M.4    Anderson, E.5    Bobrow, L.G.6    Miller, K.D.7
  • 6
    • 84869602205 scopus 로고    scopus 로고
    • HER-2. Available at
    • NordiQC. Assessment Run B4 2007; HER-2. Available at: http://www.nordiqc.org/Run-21-B4/Assessment/assessment-HER-2.htm.
    • (2007) Assessment Run B4
  • 7
    • 84869602871 scopus 로고    scopus 로고
    • estrogen receptor alpha (ER). Available at
    • NordiQC. Assessment Run B3 2007; estrogen receptor alpha (ER). Available at: http://www.nordiqc.org/Run-20-B3/Assessment/assessment-ER.htm.
    • (2007) Assessment Run B3
  • 8
    • 34547093854 scopus 로고    scopus 로고
    • News: Newfoundland launches judicial inquiry
    • Quinn M. News: Newfoundland launches judicial inquiry. CMAJ. 2007;177:24-25.
    • (2007) CMAJ , vol.177 , pp. 24-25
    • Quinn, M.1
  • 9
    • 33748269365 scopus 로고    scopus 로고
    • Quantification of immunohistochemistry - Issues concerning methods, utility and semiquantitative assessment II
    • DOI 10.1111/j.1365-2559.2006.02513.x
    • Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49:411-424. (Pubitemid 44401549)
    • (2006) Histopathology , vol.49 , Issue.4 , pp. 411-424
    • Taylor, C.R.1    Levenson, R.M.2
  • 11
    • 49149104382 scopus 로고    scopus 로고
    • Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer
    • Hanna W, O'malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol. 2007;14:149-153.
    • (2007) Curr Oncol , vol.14 , pp. 149-153
    • Hanna, W.1    O'Malley, F.P.2    Barnes, P.3
  • 12
    • 3543141103 scopus 로고    scopus 로고
    • Long-term preservation of antigenicity on tissue microarrays
    • DOI 10.1038/labinvest.3700131
    • DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest. 2004;84: 1071-1078. (Pubitemid 39025041)
    • (2004) Laboratory Investigation , vol.84 , Issue.8 , pp. 1071-1078
    • Divito, K.A.1    Charette, L.A.2    Rimm, D.L.3    Camp, R.L.4
  • 13
    • 0032896905 scopus 로고    scopus 로고
    • Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer
    • Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
    • (1999) J Clin Oncol , vol.17 , pp. 1474-1481
    • Harvey, J.M.1    Clark, G.M.2    Osborne, C.K.3
  • 15
    • 0017360990 scopus 로고
    • The measurement of observer agreement for categorical data
    • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
    • (1977) Biometrics , vol.33 , pp. 159-174
    • Landis, J.R.1    Koch, G.G.2
  • 16
    • 0036161321 scopus 로고    scopus 로고
    • HER2 testing in patients with breast cancer: Poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization
    • Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
    • (2002) Mayo Clin Proc , vol.77 , pp. 148-154
    • Perez, E.A.1    Roche, P.C.2    Jenkins, R.B.3
  • 17
    • 45149133723 scopus 로고    scopus 로고
    • Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables
    • Rasmussen BB, Andersson M, Christensen IJ, et al. Evaluation of and quality assurance in HER2 analysis in breast carcinomas from patients registered in Danish Breast Cancer Group (DBCG) in the period of 2002-2006. A nationwide study including correlation between HER-2 status and other prognostic variables. Acta Oncol. 2008;47:784-788.
    • (2008) Acta Oncol , vol.47 , pp. 784-788
    • Rasmussen, B.B.1    Andersson, M.2    Christensen, I.J.3
  • 18
    • 33745986327 scopus 로고    scopus 로고
    • HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial
    • Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032-3038.
    • (2006) J Clin Oncol , vol.24 , pp. 3032-3038
    • Perez, E.A.1    Suman, V.J.2    Davidson, N.E.3
  • 19
    • 0037024478 scopus 로고    scopus 로고
    • Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831
    • Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857.
    • (2002) J Natl Cancer Inst , vol.94 , pp. 855-857
    • Roche, P.C.1    Suman, V.J.2    Jenkins, R.B.3
  • 20
    • 33745877913 scopus 로고    scopus 로고
    • Concordance between central and local laboratory HER2 testing from a community-based clinical study
    • Reddy JC, Reimann JD, Anderson SM, et al. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer. 2006;7:153-157.
    • (2006) Clin Breast Cancer , vol.7 , pp. 153-157
    • Reddy, J.C.1    Reimann, J.D.2    Anderson, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.